{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T21:48:36Z","timestamp":1795211316799,"version":"4.10.3"},"reference-count":24,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T00:00:00Z","timestamp":1564444800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA158167"],"award-info":[{"award-number":["R01 CA158167"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24CA172123"],"award-info":[{"award-number":["K24CA172123"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA166376"],"award-info":[{"award-number":["R01 CA166376"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA121974"],"award-info":[{"award-number":["P50 CA121974"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA227473"],"award-info":[{"award-number":["R01 CA227473"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01 CA204002"],"award-info":[{"award-number":["R01 CA204002"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["KL2 TR000140"],"award-info":[{"award-number":["KL2 TR000140"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005190","name":"Melanoma Research Alliance","doi-asserted-by":"publisher","award":["308721"],"award-info":[{"award-number":["308721"]}],"id":[{"id":"10.13039\/100005190","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000048","name":"American Cancer Society","doi-asserted-by":"publisher","award":["30157-RSG-16-216-01-TBG"],"award-info":[{"award-number":["30157-RSG-16-216-01-TBG"]}],"id":[{"id":"10.13039\/100000048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s40425-019-0684-z","type":"journal-article","created":{"date-parts":[[2019,7,30]],"date-time":"2019-07-30T14:04:31Z","timestamp":1564495471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Perilesional edema in brain metastases: potential causes and implications for treatment with immune therapy"],"prefix":"10.1136","volume":"7","author":[{"given":"Thuy T.","family":"Tran","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Mahajan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica L.","family":"Chiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah B.","family":"Goldberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Don X.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia B.","family":"Jilaveanu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harriet M.","family":"Kluger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2019,7,30]]},"reference":[{"key":"684_CR1","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.clindermatol.2012.08.008","volume":"31","author":"JC Flanigan","year":"2013","unstructured":"Flanigan JC, Jilaveanu LB, Chiang VL, Kluger HM. Advances in therapy for melanoma brain metastases. Clin Dermatol. 2013;31:264\u201381.","journal-title":"Clin Dermatol"},{"key":"684_CR2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00508-017-1285-9","volume":"130","author":"C Thallinger","year":"2018","unstructured":"Thallinger C, Fureder T, Preusser M, Heller G, Mullauer L, Holler C, Prosch H, Frank N, Swierzewski R, Berger W, et al. Review of cancer treatment with immune checkpoint inhibitors : current concepts, expectations, limitations and pitfalls. Wien Klin Wochenschr. 2018;130:85\u201391.","journal-title":"Wien Klin Wochenschr"},{"key":"684_CR3","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/S1470-2045(17)30429-1","volume":"18","author":"MA Davies","year":"2017","unstructured":"Davies MA, Saiag P, Robert C, Grob JJ, Flaherty KT, Arance A, Chiarion-Sileni V, Thomas L, Lesimple T, Mortier L, et al. Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017;18:863\u201373.","journal-title":"Lancet Oncol"},{"key":"684_CR4","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1470-2045(16)30053-5","volume":"17","author":"SB Goldberg","year":"2016","unstructured":"Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976\u201383.","journal-title":"Lancet Oncol"},{"key":"684_CR5","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(12)70090-6","volume":"13","author":"K Margolin","year":"2012","unstructured":"Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol. 2012;13:459\u201365.","journal-title":"Lancet Oncol"},{"key":"684_CR6","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1016\/S1470-2045(18)30139-6","volume":"19","author":"GV Long","year":"2018","unstructured":"Long GV, Atkinson V, Lo S, Sandhu S, Guminski AD, Brown MP, Wilmott JS, Edwards J, Gonzalez M, Scolyer RA, et al. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study. Lancet Oncol. 2018;19:672\u201381.","journal-title":"Lancet Oncol"},{"key":"684_CR7","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1056\/NEJMoa1805453","volume":"379","author":"HA Tawbi","year":"2018","unstructured":"Tawbi HA, Forsyth PA, Algazi A, Hamid O, Hodi FS, Moschos SJ, Khushalani NI, Lewis K, Lao CD, Postow MA, et al. Combined Nivolumab and Ipilimumab in melanoma metastatic to the brain. N Engl J Med. 2018;379:722\u201330.","journal-title":"N Engl J Med"},{"key":"684_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1586\/ecp.11.1","volume":"4","author":"J Dietrich","year":"2011","unstructured":"Dietrich J, Rao K, Pastorino S, Kesari S. Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin Pharmacol. 2011;4:233\u201342.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"684_CR9","doi-asserted-by":"publisher","first-page":"871","DOI":"10.21873\/anticanres.11392","volume":"37","author":"J Kerschbaumer","year":"2017","unstructured":"Kerschbaumer J, Bauer M, Popovscaia M, Grams AE, Thome C, Freyschlag CF. Correlation of tumor and Peritumoral edema volumes with survival in patients with cerebral metastases. Anticancer Res. 2017;37:871\u20135.","journal-title":"Anticancer Res"},{"key":"684_CR10","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.devcel.2009.01.004","volume":"16","author":"E Dejana","year":"2009","unstructured":"Dejana E, Tournier-Lasserve E, Weinstein BM. The control of vascular integrity by endothelial cell junctions: molecular basis and pathological implications. Dev Cell. 2009;16:209\u201321.","journal-title":"Dev Cell"},{"key":"684_CR11","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.3390\/ijms14011383","volume":"14","author":"I Wilhelm","year":"2013","unstructured":"Wilhelm I, Molnar J, Fazakas C, Hasko J, Krizbai IA. Role of the blood-brain barrier in the formation of brain metastases. Int J Mol Sci. 2013;14:1383\u2013411.","journal-title":"Int J Mol Sci"},{"key":"684_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1200\/JCO.18.00204","volume":"37","author":"HM Kluger","year":"2019","unstructured":"Kluger HM, Chiang V, Mahajan A, Zito CR, Sznol M, Tran T, Weiss SA, Cohen JV, Yu J, Hegde U, et al. Long-term survival of patients with melanoma with active brain metastases treated with Pembrolizumab on a phase II trial. J Clin Oncol. 2019;37:52\u201360.","journal-title":"J Clin Oncol"},{"key":"684_CR13","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1038\/srep01364","volume":"3","author":"J Egger","year":"2013","unstructured":"Egger J, Kapur T, Fedorov A, Pieper S, Miller JV, Veeraraghavan H, Freisleben B, Golby AJ, Nimsky C, Kikinis R. GBM volumetry using the 3D slicer medical image computing platform. Sci Rep. 2013;3:1364.","journal-title":"Sci Rep"},{"key":"684_CR14","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4614-7657-3","volume-title":"Intraoperative imaging and image-guided therapy","author":"FA Jolesz","year":"2014","unstructured":"Jolesz FA. Intraoperative imaging and image-guided therapy. New York: Springer; 2014."},{"key":"684_CR15","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","volume":"30","author":"A Fedorov","year":"2012","unstructured":"Fedorov A, Beichel R, Kalpathy-Cramer J, Finet J, Fillion-Robin JC, Pujol S, Bauer C, Jennings D, Fennessy F, Sonka M, et al. 3D slicer as an image computing platform for the quantitative imaging network. Magn Reson Imaging. 2012;30:1323\u201341.","journal-title":"Magn Reson Imaging"},{"key":"684_CR16","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm791","volume":"8","author":"RL Camp","year":"2002","unstructured":"Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med. 2002;8:1323\u20137.","journal-title":"Nat Med"},{"key":"684_CR17","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1158\/1078-0432.CCR-14-0861","volume":"21","author":"LB Jilaveanu","year":"2015","unstructured":"Jilaveanu LB, Parisi F, Barr ML, Zito CR, Cruz-Munoz W, Kerbel RS, Rimm DL, Bosenberg MW, Halaban R, Kluger Y, Kluger HM. PLEKHA5 as a biomarker and potential mediator of melanoma brain metastasis. Clin Cancer Res. 2015;21:2138\u201347.","journal-title":"Clin Cancer Res"},{"key":"684_CR18","doi-asserted-by":"publisher","first-page":"3188","DOI":"10.1158\/0008-5472.CAN-05-2674","volume":"66","author":"TX Xie","year":"2006","unstructured":"Xie TX, Huang FJ, Aldape KD, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res. 2006;66:3188\u201396.","journal-title":"Cancer Res"},{"key":"684_CR19","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1038\/nature08021","volume":"459","author":"PD Bos","year":"2009","unstructured":"Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, Nguyen DX, Minn AJ, van de Vijver MJ, Gerald WL, Foekens JA, Massague J. Genes that mediate breast cancer metastasis to the brain. Nature. 2009;459:1005\u20139.","journal-title":"Nature"},{"key":"684_CR20","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.bbrc.2006.02.094","volume":"342","author":"J Li","year":"2006","unstructured":"Li J, Shi M, Cao Y, Yuan W, Pang T, Li B, Sun Z, Chen L, Zhao RC. Knockdown of hypoxia-inducible factor-1alpha in breast carcinoma MCF-7 cells results in reduced tumor growth and increased sensitivity to methotrexate. Biochem Biophys Res Commun. 2006;342:1341\u201351.","journal-title":"Biochem Biophys Res Commun"},{"key":"684_CR21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1177\/2211068214561025","volume":"20","author":"B Srinivasan","year":"2015","unstructured":"Srinivasan B, Kolli AR, Esch MB, Abaci HE, Shuler ML, Hickman JJ. TEER measurement techniques for in vitro barrier model systems. J Lab Autom. 2015;20:107\u201326.","journal-title":"J Lab Autom"},{"key":"684_CR22","doi-asserted-by":"crossref","unstructured":"Ricciuti B, Dahlberg SE, Adeni A, Sholl LM, Nishino M, Awad MM. Immune checkpoint inhibitor outcomes for patients with non-small-cell lung Cancer receiving baseline corticosteroids for palliative versus nonpalliative indications. J Clin Oncol. 2019:JCO1900189.","DOI":"10.1200\/JCO.19.00189"},{"key":"684_CR23","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00381-016-3240-x","volume":"32","author":"R Murayi","year":"2016","unstructured":"Murayi R, Chittiboina P. Glucocorticoids in the management of peritumoral brain edema: a review of molecular mechanisms. Childs Nerv Syst. 2016;32:2293\u2013302.","journal-title":"Childs Nerv Syst"},{"key":"684_CR24","doi-asserted-by":"publisher","first-page":"e20758","DOI":"10.1371\/journal.pone.0020758","volume":"6","author":"C Fazakas","year":"2011","unstructured":"Fazakas C, Wilhelm I, Nagyoszi P, Farkas AE, Hasko J, Molnar J, Bauer H, Bauer HC, Ayaydin F, Dung NT, et al. Transmigration of melanoma cells through the blood-brain barrier: role of endothelial tight junctions and melanoma-released serine proteases. PLoS One. 2011;6:e20758.","journal-title":"PLoS One"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s40425-019-0684-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-019-0684-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:44:51Z","timestamp":1601055891000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-019-0684-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,30]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["684"],"URL":"https:\/\/doi.org\/10.1186\/s40425-019-0684-z","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,7,30]]},"assertion":[{"value":"20 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the Yale University Institutional Review Board and done in accordance with international standards of good practice. All patients were provided written informed consent at enrollment.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"H.K. reports research grants from Merck, Bristol-Myers Squibb, and Apexigen during the conduct of the study, and personal fees from Regeneron, Alexion, Prometheus, Corvus, Nektar, Biodesix, Roche-Genetech, Pfizer, Iovance, Immunocore, and Celldex, outside of the submitted work. S.G. reports consulting work for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Genentech, Amgen, and Spectrum. All remaining authors have declared no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}